Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Its product candidates include UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Additionally, the Company is engaged in evaluating its lead investigational small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	37Cr 32Cr 30Cr 28Cr 53Cr 3.54TCr 53Cr 357.95Cr 139.31Cr 1.74TCr 139.21Cr 136.16Cr 6.02TCr	P/E 2023	-1.23x	P/E 2024	-2.26x
Enterprise Value	36Cr 32Cr 29Cr 27Cr 52Cr 3.47TCr 52Cr 351.58Cr 136.83Cr 1.7TCr 136.73Cr 133.73Cr 5.91TCr	EV / Sales 2023	475x	EV / Sales 2024	3,650x
Free-Float	47.41%	Yield 2023 *	-	Yield 2024	-

02/25/02	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
30/25/30	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI
30/25/30	Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics	RE
30/25/30	Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit	MT
30/25/30	Checkpoint Therapeutics, Inc. Appoints Zvi Albert as Chief Financial Officer	CI
30/25/30	Checkpoint Therapeutics, Inc. Announces Board and Executive Changes	CI
30/25/30	Checkpoint Therapeutics, Inc.(NasdaqGM:CKPT) dropped from NASDAQ Composite Index	CI
14/25/14	Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
28/25/28	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/25/28	Checkpoint Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/25/11	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
10/25/10	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
10/25/10	Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday	MT

11/25/11	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
10/25/10	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
20/23/20	B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	MT
22/23/22	B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	MT
15/23/15	Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	MT

30/25/30	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics	AQ
14/25/14	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates	AQ
29/25/29	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU
28/25/28	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates	AQ
14/25/14	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU

22/24/22	Avery Dennison Corporation : Todo lo que busca
19/24/19	Zscaler, Inc.: de kunst van de Zero Trust-aanpak
17/24/17	Zscaler: l'arte dell'approccio zero trust
16/24/16	Zscaler, Inc.: El arte del enfoque de confianza cero
16/24/16	Zscaler : l'art de l'approche zero trust

Checkpoint Therapeutics Inc Share Price Other OTC

Stocks

US1628281073

Biotechnology & Medical Research

Valuation: Checkpoint Therapeutics Inc

Latest news : Checkpoint Therapeutics Inc

Analysts' recommendations: Checkpoint Therapeutics Inc

Press Releases: Checkpoint Therapeutics Inc

News in other languages: Checkpoint Therapeutics Inc

Quotes and Performance

Managers and Directors: Checkpoint Therapeutics Inc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHECKPOINT THERAPEUTICS INC	-0.50%	+2.05%	-	-	36Cr
ARGENX SE	-0.86%	-0.64%	+73.04%	+131.53%	5.77TCr
WUXI APPTEC CO., LTD.	-0.93%	-2.54%	+73.64%	+93.71%	5.47TCr
BIONTECH SE	-3.71%	-0.35%	-14.61%	-11.19%	2.38TCr
INSMED INCORPORATED	-0.05%	+6.49%	+14.05%	+451.36%	2.42TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.80%	+5.95%	+46.35%	-3.02%	1.98TCr
GENMAB A/S	+2.02%	+6.34%	+40.74%	-29.60%	1.71TCr
PHARMAESSENTIA CORPORATION	+3.58%	+13.78%	+196.41%	+348.55%	1.68TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.58%	+16.80%	+44.58%	-	1.56TCr
EXELIXIS, INC.	-0.57%	+2.30%	+20.33%	+187.27%	1.4TCr
Average	-0.67%	+5.80%	+54.95%	+146.08%	2.71TCr
Weighted average by Cap.	-0.83%	+4.15%	+57.97%	+137.06%

	2023	2024
Net sales	1L 90.21T 83.09T 77.12T 1L 98.25L 1L 10L 4L 48.23L 4L 4L 1.67Cr	41T 35.91T 33.07T 30.7T 58.3T 39.11L 59.09T 4L 2L 19.2L 2L 2L 66.56L
Net income	-5.18Cr -4.54Cr -4.18Cr -3.88Cr -7.37Cr -494.56Cr -7.47Cr -50Cr -19Cr -242.76Cr -19Cr -19Cr -841.68Cr	-5.62Cr -4.93Cr -4.54Cr -4.21Cr -8Cr -536.46Cr -8.1Cr -54Cr -21Cr -263.33Cr -21Cr -21Cr -912.99Cr
Net Debt	-49.28L -43.16L -39.75L -36.9L -70.07L -47Cr -71.02L -4.76Cr -1.85Cr -23Cr -1.85Cr -1.81Cr -80Cr	-66.04L -57.84L -53.27L -49.45L -93.9L -63Cr -95.17L -6.38Cr -2.48Cr -31Cr -2.48Cr -2.43Cr -107.21Cr